Literature DB >> 15710595

Effect of a single dose of rituximab in chronic immune thrombocytopenic purpura in childhood.

Tillmann Taube, Hansjörg Schmid, Harald Reinhard, Arend von Stackelberg, Ursula Schulte Overberg.   

Abstract

Twenty-two children with immune thrombocytopenic purpura (ITP) with long-lasting thrombocytopenia, adversely affecting their quality of life, were treated with a reduced rituximab regimen in order to eliminate B cells producing anti-platelet antibody. A single dose of rituximab resulted in a response rate similar to that reported for cases in which 4 doses of rituximab were used.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15710595

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


  14 in total

1.  Persistent B-cell depletion after rituximab for thrombocytopenic purpura.

Authors:  Gianni Bisogno
Journal:  Eur J Pediatr       Date:  2006-08-03       Impact factor: 3.183

Review 2.  Treatment with rituximab in benign and malignant hematologic disorders in children.

Authors:  Lisa B Giulino; James B Bussel; Ellis J Neufeld
Journal:  J Pediatr       Date:  2007-04       Impact factor: 4.406

3.  Long-term follow-up of children with refractory immune thrombocytopenia treated with rituximab.

Authors:  Kousaku Matsubara; Yoshiyuki Takahashi; Akira Hayakawa; Fumiko Tanaka; Hisaya Nakadate; Michio Sakai; Naoko Maeda; Toshiaki Oka; Eiichi Ishii; Fumio Bessho; Tsuyoshi Morimoto; Hiroaki Goto; Yoshiko Hashii; Naoki Hatakeyama; Akira Shirahata; Masue Imaizumi
Journal:  Int J Hematol       Date:  2014-03-08       Impact factor: 2.490

Review 4.  The long-term impact of rituximab for childhood immune thrombocytopenia.

Authors:  Nichola Cooper; James B Bussel
Journal:  Curr Rheumatol Rep       Date:  2010-04       Impact factor: 4.592

5.  Prospective phase 1/2 study of rituximab in childhood and adolescent chronic immune thrombocytopenic purpura.

Authors:  Carolyn M Bennett; Zora R Rogers; Daniel D Kinnamon; James B Bussel; Donald H Mahoney; Thomas C Abshire; Hadi Sawaf; Theodore B Moore; Mignon L Loh; Bertil E Glader; Maggie C McCarthy; Brigitta U Mueller; Thomas A Olson; Adonis N Lorenzana; William C Mentzer; George R Buchanan; Henry A Feldman; Ellis J Neufeld
Journal:  Blood       Date:  2005-12-13       Impact factor: 22.113

Review 6.  Treatment of immune thrombocytopenic purpura in children : current concepts.

Authors:  Aziza T Shad; Corina E Gonzalez; S G Sandler
Journal:  Paediatr Drugs       Date:  2005       Impact factor: 3.022

7.  CD72 polymorphism associated with child-onset of idiopathic thrombocytopenic purpura in Chinese patients.

Authors:  Jianhui Xu; Shihong Lu; Jie Tao; Zeping Zhou; Zhenping Chen; Ying Huang; Renchi Yang
Journal:  J Clin Immunol       Date:  2008-05       Impact factor: 8.317

8.  Treatment of chronic immune thrombocytopenic purpura with rituximab in children.

Authors:  Murat Dogan; Ahmet F Oner; Mehmet Acikgoz; Abdurrahman Uner
Journal:  Indian J Pediatr       Date:  2009-11       Impact factor: 1.967

9.  Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopenia.

Authors:  Vivek L Patel; Matthieu Mahévas; Soo Y Lee; Roberto Stasi; Susanna Cunningham-Rundles; Bertrand Godeau; Julie Kanter; Ellis Neufeld; Tillmann Taube; Ugo Ramenghi; Shalini Shenoy; Mary J Ward; Nino Mihatov; Vinay L Patel; Philippe Bierling; Martin Lesser; Nichola Cooper; James B Bussel
Journal:  Blood       Date:  2012-05-07       Impact factor: 22.113

10.  Long-term remission induced by low-dose rituximab for relapsed and refractory thrombotic thrombocytopenic purpura: A report of two cases.

Authors:  Hong-Yan Tong; L I Ye; Xing-Nong Ye; DE-Min Lu; Ying Li
Journal:  Exp Ther Med       Date:  2015-10-14       Impact factor: 2.447
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.